This study aimed to evaluate the immune profile of lean and overweight-obese COPD patients. Forty patients with moderate to very severe COPD were divided into lean group (n = 20; aged 62.00 ± 8.91 years; BMI 22.26 ± 1.65 kg/m 2 ) or overweight-obese group (n = 20; aged 65.40 ± 6.69 years; BMI 29.19 ± 3.55 kg/ m 2 ). The cytokine profile (IL-2, IL-4, IL-6, IL-10, INF-γ, and TNF-α) was evaluated through the Cytometric Bead Array technique, and the expression of CD4, CD8, CD25, CD45ra, CD45ro, CD69, CD195(CCr5) and HLA-DR were evaluated in CD3+ T-cells. Overweight-obese COPD group had lower levels of IL-2 (p = 0.01) and higher INF-γ levels (p = 0.02) and IL-6 (p = 0.003) than lean COPD. Lean COPD patients had higher CD25+ (p = 0.01), CCr5 (p = 0.04) and HLA-DR (p = 0.007) expression on T cell surface compared to overweightobese COPD participants. These changes are related to immune dysfunction of obesity, and excess of fat mass in COPD can be a key factor to low T-cells activation.
Introduction
Body mass loss is one of the main determinants of low functional capacity and poor quality of life in chronic obstructive pulmonary disease (COPD) (Wilson et al., 1989; Schols et al., 1998) . Interestingly, the low body mass index (BMI) is a risk factor for mortality in severe COPD with poor ventilator capacity (Landbo et al., 1999; Prescott et al., 2002) . In addition, high BMI (ranging from 25.0 to 35.0 kg/m 2 ) exerts a protective effect in mortality of COPD patients with poor pulmonary function (Landbo et al., 1999; Prescott et al., 2002) . This obesity paradox is observed in others conditions, such in elderly individuals and chronic diseases (Poirier et al., 2006; Kim et al., 2016; Chittal et al., 2015) . On the other hand, Poulain et al. (2008 showed that airflow obstruction was less severe in overweight-obese COPD individuals compared with normal weight COPD patients, despite the higher metabolic syndrome prevalence in the former. However, obesity induces an expiratory flow limitation and airway closure, causing hypoxemia from ventilation-perfusion mismatching (Salome et al., 2010) . Moreover, obese COPD individuals also present lower forced vital capacity (FVC) compared to non-obese COPD, which may represents a restrictive abnormality (Baustista et al., 2011) .
However, both COPD and obesity conditions are associated with a low-grade systemic inflammation as potential mechanism linking to increased rate of cardiometabolic diseases (Kanneganti and Dixit, 2012) . Due to increased visceral fat mass, obesity stimulates many metabolic derangements and inflammatory disturbances such as insulin resistance, dyslipidemia and increased levels of proinflammatory tumor necrosis factor alpha (TNF-α) and interleukin-6 (IL-6) (Cildir et al., 2013) . Adipocyte hypertrophy, macrophage and T-cells infiltration, and an increase in proinflammatory cytokines production are some of the most important events in immune dysfunction of obesity (Schipper et al., 2012) . It is well known that T Lymphocytes, commonly identified by expressing CD3 on cell surface, have been implicated in obesityrelated adipose tissue inflammation (Cildir et al., 2013; Schipper et al., 2012) . Previous data reported that T-cells infiltrate into adipose tissue prior to macrophages and to contribute to the development of insulin resistance in obese individuals (Cildir et al., 2013; Chatzigeorgiou et al., 2012) . Alongside studies assessing T-cells profile, data evaluating Tcells activation status or co-stimulatory molecules also were performed. In this sense, the higher frequency of CD25+, but not CD69+ or Human Leukocyte Antigen-DR (HLA-DR), on T-cell surface was reported in unhealthy obese individuals but not in metabolically healthy obese persons (Viardot et al., 2010 (Viardot et al., , 2012 .
Multiples studies showed a strong relationship between systemic inflammation, metabolic abnormalities and higher cardiovascular diseases prevalence in COPD (Poulain et al., 2008; Breyer et al., 2009; Van der Borst et al., 2011) . In this way, tobacco smoking is the main risk factor for development of COPD, leading to pulmonary inflammation which induces pulmonary structural alterations, such as alveolar destruction and pulmonary remodeling (Sethi et al., 2012) . While pulmonary inflammation have a key role in COPD pathophysiology, systemic inflammation is also present in COPD and it is specially related to COPD exacerbations and lung function decline (Stockley, 2009 ). In addition, the presence of abdominal fat mass or overweight-obesity status in COPD patients play a key role to induction of higher levels of TNF-α and IL-6 (Van der Borst et al., 2013; Skyba et al., 2010) . For instance, the BODE index, a multidimensional system based on the body mass index, degree of airflow obstruction, dyspnea and exercise capacity, strongly correlate with C-reactive protein in COPD patients (Sarioglu et al., 2010) . In addition, the higher T-cell activation, indicating through the higher expression of HLA-DR+ on T-cells, in COPD patients contribute to elevated cytokine levels found in these patients (Tan et al., 2014; Takabatake et al., 2000; Gadgil and Duncan, 2008) . In this way, the association between COPD and obesity may represent a high risk for metabolic syndrome and cardiovascular diseases due to increases in inflammatory subclinical status (Poulain et al., 2008) .
However, to date, no data regarding the impact of overweight-obese condition on T-cell profile of COPD was found. Due to the aforementioned facts about the role of T-cells on inflammatory status in obesity, it is possible to hypothesize that excessive body mass in COPD can be a key factor to modifications in T-cells activation markers. In this line, the aim of the present study was to evaluate the immune profile of lean and overweight-obese COPD patients.
Methods

Patients
The study was approved by Institutional Ethics Committee (0302.0.005.000-08) and all participants read and signed an informed consent. We recruited 40 COPD patients of both gender: 20 overweightobese subjects with BMI greater than 27.0 kg/m ) from a pneumology ambulatory of the Irmandade Santa Casa de Misericórdia de Porto Alegre (Brazil). The diagnosis and severity of COPD were established by a pneumologist according to the Global Initiative for Chronic Obstructive Lung Disease (GOLD) criteria and all participants were classified in stages 2-4 of severity (Vogelmeier et al., 2017) . Obese and non-obese subjects were matched by age, gender and COPD severity in accordance with GOLD criteria. All patients recruited for this study were sedentary and not engaged into cardiopulmonary rehabilitation program of institution.
All participants were under clinical care with a pneumologist and presented their disease controlled, receiving standard medical treatment through bronchodilators. None of the patients were underweight or had exacerbation of the COPD in the previous 3 months. Antibiotic or oral/intravenous corticosteroids use in the last 4 weeks prior to the study was considered as exclusion criteria. Also, all individuals who had some disease of non-pulmonary origin (cardiovascular, neurological or skeletal muscle) that might interfere with the purpose of the study were excluded. Blood collection and clinical evaluations were performed in the morning (8:00-11:00).
Procedures
Body mass (kg) and height (meters) were determined by a semianalytical scale (Welmy, Santa Barbara D'Oeste, Brazil), with capacity for 200 kg and a stadiometer attached (Welmy, Santa Barbara D'Oeste, Brazil) with accuracy of 0.1 kg and 0.005 cm, respectively. BMI (kg/m 2 ) was defined as body mass (kg) divided by the square of height (m 2 ). Physical examinations and spirometric tests to assess lung function were made to define the severity of disease, and a manovacuometric test to assess respiratory muscle strength by measuring maximal inspiratory and expiratory pressures (MIP and MEP, respectively). The environment of the examinations was quiet and private, with constant temperature and humidity, the achievements of spirometry and manovacuometric followed the recommendations established by the American Thoracic Society ( 
Six minute walk test
The 6MWT was performed in a track 30 m long with measurements every 3 m demarcated on the ground as previously described (Dorneles et al., 2016) . All patients underwent to 6MWT after the blood collection, to avoid the impact of acute exercise on the inflammatory profile of COPD (Dorneles et al., 2016) . All subjects received verbal stimuli each minute to help them complete the test. We measured the heart rate and Peripheral oxygen saturarion (SpO2) by pulse oximetry (model 1001 Morrya Ipiranga, São Paulo, Brazil) and perceived exertion by the modified Borg scale (data not shown). The 6MWT followed the recommendations established by the American Thoracic Society/ European Respiratory Society (2002).
Blood collection, cytokine analysis and immunophenotyping
Patients arrived to laboratory at 8:00-9:00 a.m. in fasting state to blood collection. 10 mL of venous blood from the antecubital vein were collected in heparinized tubes by a capacitated professional. The collected material was stored in heparinized tubes to perform the analysis of the cytokine profile through the Cytometric Bead Array technique (CBA) (Becton Dickinson, San Jose, CA, USA): Interleukin-2 (IL-2), Interleukin-4 (IL-4), IL-6, Interleukin-10 (IL-10), Interferon-gamma (IFN-γ) and TNF-α. Six populations of beads with distinct fluorescence intensities were conjugated with specific capture antibody for each cytokine, mixed to form the CBA and read in the FL3 channel of the FACSCalibur flow cytometer (Becton Dickinson).
Immunophenotyping was carried out using a direct immunofluorescence technique. Monoclonal antibodies specific for CD3, CD4, CD8, CD25, CD45ra, CD45ro, CD69, CD195 (CCr5) and HLA-DR conjugated with specific fluorochromes (PE, FITc or Cy-chrome) as well as the appropriate isotype controls, were purchased from Becton Dickinson (San Jose, CA, USA). We used a two-color staining method using monoclonal antibodies labeled with fluorescein isothiocyanate and antibodies labeled with phycoerythrin added to 12 × 75 mm testtubes. Flow cytometry was performed using a FACSCalibur instrument and CellQuest software (Becton Dickinson, San Jose, CA, USA). Lymphocyte population was gated in basis of forward scatter (FSC-H) versus side scatter (SSC-H) and appropriated control antibodies as CD14 + CD45+. A minimum of 20,000 cells per gate were obtained with each sample. Data are reported as the peripheral frequency of CD3 + CD4+, CD3 + CD8+, CD3 + CD25+, CD3 + CD45ra+, CD3 + CD45ro+, CD3 + CD69+, CD3 + CCr5+ and CD3 + HLA-DR on lymphocyte gate.
Statistical analysis
Data were analyzed by SPSS 20.0 (IBM Inc., USA). Categorical data are displayed as relative frequency and compared between groups by Chi-Square or Fisher's exact test. Normality test was performed through Shapiro-Wilk test. The patient's characteristics and peripheral cytokine levels were presented as mean ± standard deviation, and the differences between groups for quantitative variables were assessed by Independent Student t-test (normal data). Immunophenotyping of Tcells from lean and overweight-obese COPD patients was considered non-parametric and presented as median (interquartile range) and compared though Mann-Whitney U test. The level of significance was set at p ≤ 0.05 in all analysis.
Results
Clinical and demographic data of lean and overweight-obese COPD patients were shown in Table 1 . As expected, overweight-obese COPD group had higher body mass (p < 0.001) and BMI (p < 0.001) than lean COPD group. Forced vital capacity (FVC) was lower in overweightobese subjects (p = 0.026), although the FEV 1 /FVC (p = 0.019) and MEP (p = 0.04) were higher compared to lean subjects. No significant differences were found in age, FEV 1, MIP or 6MWT (p > 0.05). However, no significant differences between groups were found in% of predicted for FVC or% of predicted for FEV 1 (p > 0.05). In addition, GOLD Diagnostic and gender were equal between groups (p > 0.05). Table 2 presents the cytokine levels measured in lean and overweight-obese COPD patients. Overweight-obese COPD group had low levels of IL-2 (17.31 ± 1.05 vs. 19.82 ± 2.65 pg/mL; p = 0.002), and high IL-6 (38.31 ± 10.17 vs. 31.08 ± 8.04 pg/mL; p = 0.03) and INF-γ levels (11.08 ± 2.70 pg/mL vs 8.50 ± 2.88 pg/mL; p = 0.013) than lean COPD. No significant differences were observed in IL-4, IL-10 and TNF-α levels (p > 0.05).
The peripheral frequency of CD3 + CD4+, CD3 + CD8+ or CD4+/CD8+ ratio were not different between lean and overweightobese groups (p > 0.05) (Fig. 1) . We also performed analysis of CD25+ (Fig. 2a) , CD45ra (Fig. 2b) , CD45ro (Fig. 2c), CD69 (Fig. 2d) , CCr5 (Fig. 2e) and HLA-DR (Fig. 2f ) expression on cell surface of CD3+ T-Cells (Fig. 2) A. Peres et al. Respiratory Physiology & Neurobiology 247 (2018) 
Discussion
This is the first study to demonstrate that overweight-obese COPD patients presented low expression of CD25+, HLA-DR and CCr5 on cell surface of T-cells compared to matched lean COPD patients. These immune cell differences were accompanied by low levels of IL-2 and high levels of systemic IL-6 and INF-γ in overweight-obese COPD. Collectively, this may reflect a low activation state of T-cells in overweight-obese COPD subjects.
T-cells play a key role in pathogenesis of obesity and pulmonary diseases. It was described, for example, that T-cells have been implicated in obesity-related adipose tissue inflammation (Schipper et al., 2012) . However, circulating T-cells have conflicting reports in obesity, with increasing or decreasing peripheral frequency has been reported in previous studies (Viardot et al., 2012; Ilavska et al., 2012; Nieman et al., 1999; van der Weerd et al., 2012) . In this line, we did not find significant differences in peripheral frequency of CD4+ or CD8+ Tcells among lean and overweight-obese COPD patients. These results contrasts with previous reports in non-COPD obese subjects that showed higher circulating CD4+ T-cells (Ilavska et al., 2012; AlSufyani and Mahassni, 2011; Womack et al., 2007) and lower CD8+ Tcells (O'Rourke et al., 2005; Han et al., 2011) .
However, despite the lack of differences in the peripheral frequency of CD4+ and CD8 T-cells, we find that markers of cell activation such CD25+ and HLA-DR on CD3+ T-cells was significantly lower in overweight-obese COPD patients. The low peripheral frequency of CD25+ in association with reduced IL-2 levels may reflect a decreased state of activation of T-cells in these subjects. The CD25+ is the alpha chain of IL-2 receptor expressed on the cell surface of activated lymphocytes (Létourneau et al., 2009 ). In addition, the interaction between CD25+ and IL-2 is crucial for differentiation of CD4+ and CD8+ T- Fig. 2 . Peripheral frequency of CD25+, CD45ra+, CD45ro+, CD69+, CCr5+ and HLA-DR+ on T-cell surface of lean and overweight-obese COPD patients. Differences between groups were observed through Mann-Whitney U test (p ≤ 0.05).
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Respiratory Physiology & Neurobiology 247 (2018) 74-79 cells into effector T-cells subsets following antigen-mediated activation (Boyman and Sprent, 2012) . COPD patients present lower proportion of CD25+ T-cells than healthy patients, and this decrease may play a role in the imbalance between pro-and anti-inflammatory mediators and the progression of the disease (Domagala-Kulawik et al., 2011; Hou et al., 2013) . Thus, the reduction in CD3 + CD25+ expression and IL-2 levels in overweight-obese COPD patients suggest that excess of body mass is a possible key factor for depression of immune system in COPD. However, more studies is necessary to clarify this question since other studies reporting lower expression of CD25+ on T-cells in COPD did not differentiate lean and obese subjects (Domagala-Kulawik et al., 2011; Hou et al., 2013) . HLA-DR is a subclass of major histocompability complex (MHC) class II receptor that is up regulated in response to cell signaling (Salgado et al., 2002) . Recalde et al. (1999) reported that COPD patients had significantly reduced HLA-DR expression than controls. The role of HLA-DR on exacerbation of inflammatory response was previous reported in COPD patients (Takabatake et al., 2000; Roos-Engstrand et al., 2009) . Moreover, Tan et al. (2014) reported that impaired regulatory T-cells activity, an immunosuppressive subpopulation of T-cells, in COPD patients is responsible for enhanced of T cell activation, as demonstrated through higher HLA-DR expression, and inflammatory response. Interestingly, the disturbance in adaptive immune system is similar to those found in obesity condition (Pecht et al., 2014) . In Italian national multicenter study for the definition of reference ranges of the frequency of lymphocyte subsets in a cohort of healthy adults, Santagostino et al. (1999) showed significantly lower HLA-DR expression on CD3+ T-cells in overweight subjects compared to normal weight (14.7% vs. 16.0%). Corroborating with this, it was seen that weight loss can reduce HLA-DR expression on cell surface of lymphocytes after 12 weeks in overweight-obese adults (Colato et al., 2014) . However, another activation marker used in our study, CD69, did not presented significant differences between lean and overweight-obese COPD patients (lean: 4.23 ± 3.34% vs. overweight-obese: 2.23 ± 2.04%). Our experimental data regarding CD69 corroborate the previous findings in non-COPD obese adults (Viardot et al., 2010) . This result could be explained since CD69 is an early activation marker and the COPD as well as obesity condition are characterized by a chronic inflammation state. Collectively, our results pointed that excessive body mass, as demonstrated by overweight-obesity conditions, is a key factor for depressive T cell activation state, as indicated by lower surface expression of CD25+ and HLA-DR.
In addition, overweight-obese COPD patients also displayed lower expression of CCR5+, a chemokine receptor that participates in the process of attraction to the inflamed tissue (Contento et al., 2008) . In COPD, CCR5 mediates the chemoattraction of inflammatory Th1 T-cells to bronchoalveolar lavage and lung (Brozyna et al., 2009; Leckie et al., 2003) . In this way, excess of body mass could be a protective factor to chemotaxis of inflamed cells to the lung in COPD. However, Kennedy et al. (2013) reported that CCR5-deficient mice were significantly more glucose intolerant thant wild-type mice, suggesting that lower CCR5 expression impairs systemic glucose tolerance and insulin signaling at adipose tissue and muscle skeletal tissue. More studies are needed to clarify the influence of obesity in CCR5+ and activation state in COPD patients.
Despite previous data reporting differences in TNF-α (Poulain et al., 2008) or IL-6 (Poulain et al., 2008 ) levels between obese and lean COPD patients, we did not find any changes regarding TNF-α levels. On the other hand, Skyba et al. (2010) showed higher expression of IL-6 and TNF-α in adipose tissue of COPD obese patients but not observed any changes in serum IL-6 or TNF-α. The lack of significant differences between groups in anti-inflammatory cytokines, IL-4 and IL-10, suggests that obesity induce only induce immunomodulation on proinflammatory mediators in pulmonary diseases. In addition, overweightobese group displayed higher INF-γ levels compared to lean group. The persistent inflammation of the COPD is mediated, at least in part, by Th1 phenotype of T-cells and higher production of INF-γ (Brozyna et al., 2009; Hodge et al., 2011) . Thus, obesity and body mass should be taken into account when interpreting the levels of inflammatory mediators in COPD.
Although not statistical significant, overweight-obese COPD patients walked 50 m more than lean COPD patients. On the other hand, Baustista et al. (2011) showed that COPD patients diagnosed with obesity grade 2 (BMI = 37 kg/m 2 ) had reduced distance performed in 6MWT compared with normal weight COPD patients. However, the peak of oxygen consumption, ventilation, and cardiopulmonary responses during the tests were similar between groups (Baustista et al., 2011) . Thus, although moderate obesity has no effect in functional capacity, severe obesity seems to exert negative impact in exercise performance of COPD patients. In accordance with this, O'Donnell et al. (2012) argue that the presence of mild-to-moderate obesity in COPD patients appears to have little impact on exercise performance. It was postulated that the lower operating lung volumes at rest or exercise conditions in obese COPD subjects induces a mechanical advantage for the respiratory muscle (O'Donnell et al., 2012) .
Some limitations of our study should be pointed. Firstly, the use of BMI for rating of lean or overweight-obese groups does not take into account the visceral fat mass, an important source of systemic inflammation in obesity (Baustista et al., 2011) . However, BMI is an important and practical clinical tool for the identification of risk factors. On the other hand, the intake of glucocorticoids in COPD is associated with increased water retention and BMI that could mask our results. Besides, it should be noted that patients were not taking any medications during the 4 weeks previous the test (as described in the Material and methods), although one cannot rule out a potential interference of the previous medical regimen. We also did not analyze the expression of the molecules according to the subpopulations of CD4+ and CD8+ due to methodological issues. Future studies should be performed to clarify the influence of underweight and obesity on the T-cells phenotype in accordance with activation status and memory.
Conclusion
In conclusion, our findings suggest that excessive body mass play a key role on impaired T-cells in elderly patients with COPD. Overweightobesity was associated with low activation status of T-cells, analyzed by low frequency of CD25+, HLA-DR and CCr5. In addition, overweightobese COPD presented low IL-2 levels, and higher INF-γ levels, a marker of Th1 phenotype. Despite the paradox that increased BMI is associated with better pulmonary and functional capacity, the prevention of weight gain in COPD could be important to control the low-grade inflammation.
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